Sabra Health Care REIT has delivered a strong 108.1% return over the past 3 years, yet its current valuation checks and market multiples suggest the stock is not a clear bargain. Recent share price gains sit alongside a low overall value score and an overvalued reading on traditional earnings multiples.

• The 108.1% return over 3 years highlights how strongly Sabra Health Care REIT has rewarded shareholders, which raises the bar for what counts as an attractive entry point today.
• Future income from its healthcare real estate portfolio can support valuation if occupancy and rental terms hold up, but any pressure on tenant quality or funding costs may weigh on what investors are willing to pay.
• With a value score of 2 out of 6, Sabra Health Care REIT currently appears expensive on the broader set of valuation checks rather than looking like an obvious bargain.

The key question now is whether Sabra Health Care REIT's recent performance already prices in most of the upside that its fundamentals can justify.

Is Sabra Health Care REIT Getting Expensive on Earnings?

The P/E ratio is a common way to judge how much you are paying for each dollar of earnings, which fits Sabra Health Care REIT because its profits give a clear anchor for this metric. Sabra Health Care REIT currently trades on a P/E of 79.9x, compared with an average of 17.2x for Health Care REITs. That is also materially higher than the peer group average of 40.5x, so the stock carries a clear premium to many comparable companies.

The fair P/E ratio, which reflects what investors might typically pay given Sabra Health Care REIT's size, risk profile and sector, is estimated at 52.5x. The gap between the current 79.9x and this fair ratio indicates investors are paying well above what this model suggests is reasonable for the earnings on offer. This does not rule out further upside, but it does leave less margin for disappointment if results or sentiment weaken.

On the P/E multiple, Sabra Health Care REIT currently screens as overvalued relative to both its industry and a more tailored fair-value benchmark.

The Sabra Health Care REIT Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this valuation puzzle for Sabra Health Care REIT leaves off. They spell out which assumptions about Sabra Health Care REIT's future growth, margins and earnings would need to hold for the stock to be worth meaningfully more or less than today's price. Each one sets out its own underlying fair value assumptions so you can compare them with actual results as they are reported on the Community page.

Share a narrative on Sabra Health Care REIT to present your own, number-driven view on where its growth, margins and execution go from here, and see how your thesis stacks up as new results arrive. This is a chance to add your voice to the Simply Wall St community and help other investors think through the stock.

Do you think there's more to the story for Sabra Health Care REIT? Head over to our Community to see what others are saying!

The Bottom Line

Sabra Health Care REIT currently looks overvalued on traditional earnings multiples, with the market assigning a clear premium to its P/E relative to sector peers and a tailored fair-value benchmark. That premium only makes sense if investors are comfortable that occupancy, rental terms and funding costs remain supportive. The crux for you is whether Sabra Health Care REIT can deliver the operational resilience that would justify this richer multiple, or whether expectations have simply moved ahead of what the underlying portfolio can reasonably support.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.